Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma

B. J. Tong, J. Tan, L. Tajeda, S. K. Das, J. A. Chapman, R. N. DuBois, S. K. Dey

Research output: Contribution to journalArticle

112 Scopus citations

Abstract

Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) significantly reduce the risk and mortality from colorectal cancer, in part by inhibiting prostaglandin (PG) synthesis. Cyclooxygenase (COX), the rate-limiting enzyme in PG biosynthesis, exists in two isoforms, COX-1 and COX-2. Genetic and pharmacological evidences suggest that COX-2 is involved in the development of colorectal cancer. We have previously shown that COX-2-derived prostacyclin participates in blastocyst implantation through activation of peroxisome proliferator activated receptor δ (PPARδ), a member of the nuclear hormone receptor family. Furthermore, our recent studies suggest that a similar pathway is operative during colorectal carcinogenesis. These observations prompted us to examine whether the COX-2-PPARδ signaling pathway is also involved during development of uterine adenocarcinoma. Here we describe for the first time the heightened expression of COX-2 and PPARδ, but not COX-1, in uterine endometrial adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)483-490
Number of pages8
JournalNeoplasia
Volume2
Issue number6
StatePublished - Dec 1 2000

    Fingerprint

Keywords

  • Cyclooxygenase
  • Endometrial cancer
  • Human
  • Prostaglandins
  • Uterus

ASJC Scopus subject areas

  • Cancer Research

Cite this

Tong, B. J., Tan, J., Tajeda, L., Das, S. K., Chapman, J. A., DuBois, R. N., & Dey, S. K. (2000). Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma. Neoplasia, 2(6), 483-490.